The Most Elaborate Perpetual Pump'n'Dump In Need of Shorting

AML Initial Diagnosis BAT is either a fixed duration or continuous therapy. If complete remission is achieved, patients usually survive for 18-24 months with gruelling side effects of the currently best available drugs. Should the AML relapse and CR2 be achieved, the life expectancy is grimly months, not years. GPS has proven to boost overall median survival to >60 months in first line, which was 18-24 months previously with current standard of care. 21 months in second line with GPS, comparatively less than a year with current standard of care. It’s important to note that the median overall survival (mOS) is estimated to be 6-8 months in patients who do not receive transplant in CR2. Transplant is NOT allowed in REGAL patients after CR2 and before enrollment. Transplant is the only potentially curative treatment for most AML patients, but only about 40% of AML patients can receive a transplant; approximately half of transplanted patients are cured but, even then, the patient can experience a relapse. Should a relapse happen on HMA+ventoclax combination, (the current standard of care), the survival is only about 2.5 months. Survival remains limited in patients who achieve response. GPS maintenance HAS PROVEN in earlier trials to significantly prolong survival. >60 months in first line patients in remission. 21 months in second line patients in remission. The longer the duration of REGAL phase 3, the more likely it is that the numbers will match previously done trials, if not blow them out of the water with even better results. Multiple cancers express WT1, but in AML it is more than a 95% expression. It is an over expression. GPS is an off the shelf drug, not patient specific. It is easy to administer, with no known harmful side effects aside from local reactions. It is a subcutaneous vaccine that can, with collected trial data, be administered ad infinitum with, let me repeat, safe to date the only known side effect to be a local reaction (subcutaneous injections might cause irritation around the skin where the injection administered).  Look, I could write even more, and to anyone who has read this post; I urge you to, if you haven’t yet, research into SLS. All of the above information is from last October’s virtual R&D Day. It is 2 hours long, with great slides filled with data. And doctors with actual clinical experience. GPS could be the first in class & best in class AML treatment. I think every single point of OP’s can be broken down and explained scientifically with data to back it up. It’s just a huge wall of text, pointless garbling. Even if it were to be true and GPS somehow fails; would you not want to dream big? What GPS could potentially achieve is nothing short of groundbreaking. Think of the physicians who have to break the news to their patients, that their life expectancy is months should they receive the standard of care treatment. With GPS, it could be years. It could be a monumental vaccine.